Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Liver injury in COVID-19: management and challenges1313
Prolonged presence of SARS-CoV-2 viral RNA in faecal samples1244
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017790
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis733
Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?580
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis548
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis455
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation stu396
SARS-CoV-2 in wastewater: potential health risk, but also data source373
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis345
COVID-19 and the liver: little cause for concern316
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-labe294
Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADe-DB trial): a double-blind randomised study265
Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study246
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis244
Early detection of pancreatic cancer240
Implications of COVID-19 for patients with pre-existing digestive diseases235
Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study234
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease St220
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis219
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study209
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, pha197
COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy195
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach194
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study185
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019182
The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection173
Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019160
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study143
Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder142
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study140
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study138
Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial133
Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden132
Probiotics and COVID-19: one size does not fit all131
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis127
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis126
Global multi-stakeholder endorsement of the MAFLD definition123
Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study119
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement116
Redefining fatty liver disease: an international patient perspective115
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial114
Enteric involvement in hospitalised patients with COVID-19 outside Wuhan113
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial112
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis110
Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis106
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, par105
Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study104
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement102
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial102
Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel101
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial100
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study100
Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis98
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study98
Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa97
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease96
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial95
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study95
Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial94
Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study93
Ultra-processed foods and human health: from epidemiological evidence to mechanistic insights90
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis88
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver dise88
Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis88
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study86
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomi85
Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens85
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority st84
Determining risk factors for mortality in liver transplant patients with COVID-1982
Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial81
Global prevalence of hepatitis C virus in children in 2018: a modelling study78
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial77
Gastrointestinal sequelae 90 days after discharge for COVID-1977
Current and emerging therapies for advanced biliary tract cancers77
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial76
0.050602912902832